Market Overview

Impax Labs Enters Commercialization Deal with Perrigo

Related PRGO
Nothing Generic About This ETF's Long-Term Outlook
Worst Performing Industries For April 27, 2016
Biotech Forum Daily Digest: Sarepta Plunges On Ad Comm Decision, Novartis To Be Player In M&A? Spotlight On Exelixis (Seeking Alpha)
Related IPXL
Earnings Scheduled For February 22, 2016
Benzinga's Top Initiations

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it will collaborate with Perrigo Company (NASDAQ: PRGO;TASE) on the development, manufacturing and commercialization of an extended topical generic drug product with first to market potential. The product and terms of the agreement were not disclosed.

Posted-In: News


Related Articles (IPXL + PRGO)

View Comments and Join the Discussion!